Tze Choong Charn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Tze Choong Charn has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Neville Wei Yang Teo
Department of Otorhinolaryngology‐Head and Neck Surgery Singapore General Hospital Singapore Singapore
5 shared publications - Benjamin Kye Jyn Tan
Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
4 shared publications - Shuhui Xu
Department of Otorhinolaryngology—Head and Neck Surgery, Singapore General Hospital, Singapore
4 shared publications - Anna See
Department of Otorhinolaryngology–Head & Neck Surgery Singapore General Hospital Singapore
3 shared publications - Claire Jing‐Wen Tan
Yong Loo Lin School of Medicine National University of Singapore Singapore Singapore
3 shared publications - Song Tar Toh
Singapore General Hospital
3 shared publications
Latest Publications
- Open Access
- 10 July 2025
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 15 (12) , 1347-1358
Olfactory Impairment and Incident Cognitive Decline: A Systematic Review and Meta‐Analysis
Background: Olfactory impairment (OI) is associated with poor ageing outcomes. While cross‐sectional studies found a high prevalence of OI among patients with neurodegenerative diseases, the temporal relationship remains unclear. This meta‐analysis aims to synthesise the longitudinal association of OI with cognitive decline (CD). Methods: PubMed, Embase and Web of Science were searched through August 9, 2024 for longitudinal studies reporting on self‐reported and objectively measured OI in adults, in association with CD, measured using validated methods. The outcome of interest was incident CD. Independent authors extracted data, assessed for bias and graded the strength of evidence. A mixed‐effects meta‐analysis with subgroup, sensitivity and bias analyses was conducted. The population‐attributable fraction (PAF) of OI‐associated CD was calculated. Results: This study included 48 articles and 37,783 participants. OI patients had a 2.06‐fold greater risk of any CD (risk ratio [RR] = 2.06; 95% CI = 1.87‒2.26, I 2 = 0%), compared to individuals with normal olfaction. Patients with severe OI had a higher risk of any CD (RR = 2.60; 95% CI = 2.12‒3.20, I 2 = 0%) than patients with moderate OI (RR = 1.51; 95% CI = 1.23‒1.85, I 2 = 0%). The risk of any CD increased by 18% per 10% decrease in olfactory score (RR = 1.18; 95% CI = 1.14‒1.22, I 2 = 24%) and by 15% per point decrement on the Sniffin’ Sticks Odor Identification Test (RR = 1.15; 95% CI = 1.11‒1.18, I 2 = 0%). These results remained robust to supplementary analyses. The PAF of OI‐associated incident CD was 18%. Conclusion: OI may increase the risk of CD, with poorer olfaction linked to greater risks. OI should be assessed as a potential cognitive screening tool, and cognitive screening should be considered in patients with long‐standing OI.
- 10 July 2025
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 15 (12) , 1347-1358
Open AccessOlfactory Impairment and Incident Cognitive Decline: A Systematic Review and Meta‐Analysis
Background: Olfactory impairment (OI) is associated with poor ageing outcomes. While cross‐sectional studies found a high prevalence of OI among patients with neurodegenerative diseases, the temporal relationship remains unclear. This meta‐analysis aims to synthesise the longitudinal association of OI with cognitive decline (CD). Methods: PubMed, Embase and Web of Science were searched through August 9, 2024 for longitudinal studies reporting on self‐reported and objectively measured OI in adults, in association with CD, measured using validated methods. The outcome of interest was incident CD. Independent authors extracted data, assessed for bias and graded the strength of evidence. A mixed‐effects meta‐analysis with subgroup, sensitivity and bias analyses was conducted. The population‐attributable fraction (PAF) of OI‐associated CD was calculated. Results: This study included 48 articles and 37,783 participants. OI patients had a 2.06‐fold greater risk of any CD (risk ratio [RR] = 2.06; 95% CI = 1.87‒2.26, I 2 = 0%), compared to individuals with normal olfaction. Patients with severe OI had a higher risk of any CD (RR = 2.60; 95% CI = 2.12‒3.20, I 2 = 0%) than patients with moderate OI (RR = 1.51; 95% CI = 1.23‒1.85, I 2 = 0%). The risk of any CD increased by 18% per 10% decrease in olfactory score (RR = 1.18; 95% CI = 1.14‒1.22, I 2 = 24%) and by 15% per point decrement on the Sniffin’ Sticks Odor Identification Test (RR = 1.15; 95% CI = 1.11‒1.18, I 2 = 0%). These results remained robust to supplementary analyses. The PAF of OI‐associated incident CD was 18%. Conclusion: OI may increase the risk of CD, with poorer olfaction linked to greater risks. OI should be assessed as a potential cognitive screening tool, and cognitive screening should be considered in patients with long‐standing OI.
- 18 March 2024
- Published by Springer Nature in Indian Journal of Otolaryngology and Head & Neck Surgery
- Vol. 76 (4) , 3018-3030
A Comparison of Tranexamic Acid in Nasal Versus Sinus Surgeries: a Systematic Review and Meta-Analysis
Nasal surgeries (e.g.: rhinoplasties, septoplasties) and sinus surgeries (e.g.: Functional Endoscopic Sinus Surgeries) are common procedures in Otorhinolaryngology. Tranexamic acid (TXA), an antifibrinolytic drug, has been increasingly utilized to reduce hemorrhage recently. While close in proximity anatomically, the bleeding nature of sinus and nasal surgeries may differ. We present the first meta-analysis that has reviewed both nasal and sinus surgery collectively and compares the two. Pubmed, Embase, Cochrane Library and WoS were searched until April 2023. Outcomes of interest include Boezart Scoring, clotting time, postoperative complications and surgical field quality. 27 Studies were assessed, of which 25 studies were evaluated quantitatively. Of the 27 studies, 15 studies involved Sinus surgery while 12 involved Nasal surgery. The use of tranexamic acid was notably beneficial in the evaluation of blood loss, reduction of operating time, surgical field quality and surgeon satisfaction. TXA has proven to be efficacious in both nasal and sinus surgeries to varying degrees. TXA has more effects in sinus surgeries compared to nasal surgeries in objective markers such as reducing blood loss and operating time, but the converse occurs for subjective markers such as surgeon satisfaction scores.
- 18 March 2024
- Published by Springer Nature in Indian Journal of Otolaryngology and Head & Neck Surgery
- Vol. 76 (4) , 3018-3030
A Comparison of Tranexamic Acid in Nasal Versus Sinus Surgeries: a Systematic Review and Meta-Analysis
Nasal surgeries (e.g.: rhinoplasties, septoplasties) and sinus surgeries (e.g.: Functional Endoscopic Sinus Surgeries) are common procedures in Otorhinolaryngology. Tranexamic acid (TXA), an antifibrinolytic drug, has been increasingly utilized to reduce hemorrhage recently. While close in proximity anatomically, the bleeding nature of sinus and nasal surgeries may differ. We present the first meta-analysis that has reviewed both nasal and sinus surgery collectively and compares the two. Pubmed, Embase, Cochrane Library and WoS were searched until April 2023. Outcomes of interest include Boezart Scoring, clotting time, postoperative complications and surgical field quality. 27 Studies were assessed, of which 25 studies were evaluated quantitatively. Of the 27 studies, 15 studies involved Sinus surgery while 12 involved Nasal surgery. The use of tranexamic acid was notably beneficial in the evaluation of blood loss, reduction of operating time, surgical field quality and surgeon satisfaction. TXA has proven to be efficacious in both nasal and sinus surgeries to varying degrees. TXA has more effects in sinus surgeries compared to nasal surgeries in objective markers such as reducing blood loss and operating time, but the converse occurs for subjective markers such as surgeon satisfaction scores.
- 18 December 2023
- Published by Elsevier in American Journal of Otolaryngology
- Vol. 45 (2) , 104206
The association between chronic sinonasal inflammation and nasopharyngeal carcinoma - A systematic review and meta-analysis
- 18 December 2023
- Published by Elsevier in American Journal of Otolaryngology
- Vol. 45 (2) , 104206
The association between chronic sinonasal inflammation and nasopharyngeal carcinoma - A systematic review and meta-analysis
- 20 October 2023
- Published by Wiley in Clinical Otolaryngology
- Vol. 49 (1) , 29-40
Meta‐analysis of multi‐modality therapies in sinonasal undifferentiated carcinoma—A timely update
Objectives: Sinonasal undifferentiated carcinoma (SNUC) is a rare but aggressive tumour with very poor prognosis. There are currently no well-established clinical trials to guide therapy and the impact of various treatment modalities on survival is not well defined. We aim to provide an updated systematic review on current treatment modalities on survival outcomes.Design and Setting: Individual patient data were extracted, and survival data pooled in a one-stage meta-analysis. Descriptive statistics were analysed using the Kaplan-Meier method. Patient-level comparisons stratified by treatment modalities, adjusted for demographics, were conducted using shared-frailty Cox regression.Participants and Main outcome measures: Participants include all patients diagnosed with SNUC based on histological evidence. We looked at the overall cumulative survival outcome for different treatment modalities and overall survival by treatment modality in low versus high stage SNUC patients.Results and Conclusion: Seventeen studies were identified, comprising 208 patients from 1993 to 2020. There was no significant difference in cumulative overall survival in low versus high stage patients, and no significant difference in outcomes by treatment modality. The overall cumulative survival of SNUC is 30% at 95 months. Among patients treated with various combinations of treatment modalities, patients with chemoradiotherapy had the highest cumulative survival of 42% at 40 months. Definitive chemoradiotherapy was associated with improved disease survival rate. Regardless of tumour stage, patients should be treated early and aggressively, with no superiority of one treatment regimen over another. Trimodality treatment does not confer survival advantage over bimodality treatment.
- 20 October 2023
- Published by Wiley in Clinical Otolaryngology
- Vol. 49 (1) , 29-40
Meta‐analysis of multi‐modality therapies in sinonasal undifferentiated carcinoma—A timely update
Objectives: Sinonasal undifferentiated carcinoma (SNUC) is a rare but aggressive tumour with very poor prognosis. There are currently no well-established clinical trials to guide therapy and the impact of various treatment modalities on survival is not well defined. We aim to provide an updated systematic review on current treatment modalities on survival outcomes.Design and Setting: Individual patient data were extracted, and survival data pooled in a one-stage meta-analysis. Descriptive statistics were analysed using the Kaplan-Meier method. Patient-level comparisons stratified by treatment modalities, adjusted for demographics, were conducted using shared-frailty Cox regression.Participants and Main outcome measures: Participants include all patients diagnosed with SNUC based on histological evidence. We looked at the overall cumulative survival outcome for different treatment modalities and overall survival by treatment modality in low versus high stage SNUC patients.Results and Conclusion: Seventeen studies were identified, comprising 208 patients from 1993 to 2020. There was no significant difference in cumulative overall survival in low versus high stage patients, and no significant difference in outcomes by treatment modality. The overall cumulative survival of SNUC is 30% at 95 months. Among patients treated with various combinations of treatment modalities, patients with chemoradiotherapy had the highest cumulative survival of 42% at 40 months. Definitive chemoradiotherapy was associated with improved disease survival rate. Regardless of tumour stage, patients should be treated early and aggressively, with no superiority of one treatment regimen over another. Trimodality treatment does not confer survival advantage over bimodality treatment.
- 12 July 2023
- Published by Taylor & Francis in Immunotherapy
- Vol. 15 (14) , 1105-1116
Mepolizumab in Chronic Rhinosinusitis with Nasal Polyposis
Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a heterogeneous upper airway disease that is prevalent globally. Recent research into the molecular basis of the disease has led to the devel... Plain language summary Mepolizumab is a new injectable drug developed to control difficult-to-treat cases of chronic rhinosinusitis with nasal polyposis (CRSwNP), an inflammatory disease of the nos... Tweetable abstract Mepolizumab is a monoclonal antibody targeting IL-5, a cytokine and principal driver of disease in CRSwNP. We present the latest evidence behind mepolizumab, discuss practical is...
- 12 July 2023
- Published by Taylor & Francis in Immunotherapy
- Vol. 15 (14) , 1105-1116
Mepolizumab in Chronic Rhinosinusitis with Nasal Polyposis
Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a heterogeneous upper airway disease that is prevalent globally. Recent research into the molecular basis of the disease has led to the devel... Plain language summary Mepolizumab is a new injectable drug developed to control difficult-to-treat cases of chronic rhinosinusitis with nasal polyposis (CRSwNP), an inflammatory disease of the nos... Tweetable abstract Mepolizumab is a monoclonal antibody targeting IL-5, a cytokine and principal driver of disease in CRSwNP. We present the latest evidence behind mepolizumab, discuss practical is...
- 31 March 2023
- Published by Cambridge University Press (CUP) in The Journal of Laryngology & Otology
- Vol. 137 (12) , 1300-1311
Role of probiotics in chronic rhinosinusitis: a systematic review of randomised, controlled trials
Objective: This review evaluated the safety profile and efficacy of probiotics in chronic rhinosinusitis and was registered with Prospero (Centre for Reviews and Dissemination number: 42020193529).Method: Literature databases were searched through inception to August 2022. Randomised, controlled trials exploring adjunctive probiotics in adult chronic rhinosinusitis patients were included. From 948 records screened, 4 randomised, controlled trials were included.Results: Probiotics-associated adverse effects comprised epistaxis and abdominal pain. No reduction in Sino-Nasal Outcome Test values before 4 weeks (p = 0.58) or beyond 8 weeks (p = 0.08) of treatment or reduction of severe symptom frequency (p = 0.75) was observed. Symptom relapse in probiotic-treated patients was significantly lower across all timepoints (p = 0.045). Lower sinusitis relapse risks during treatment (risk ratio = 0.49; p = 0.019) and 8 months post-treatment (risk ratio = 0.56, p = 0.013) were observed. Probiotics demonstrated potential in improving Sino-Nasal Outcome Test symptom subscales, including sleep, psychological and rhinology subscales.Conclusion: The optimal mode of probiotic administration, treatment duration and target patient subgroups requires further study to evaluate the utility of probiotics.
- 31 March 2023
- Published by Cambridge University Press (CUP) in The Journal of Laryngology & Otology
- Vol. 137 (12) , 1300-1311
Role of probiotics in chronic rhinosinusitis: a systematic review of randomised, controlled trials
Objective: This review evaluated the safety profile and efficacy of probiotics in chronic rhinosinusitis and was registered with Prospero (Centre for Reviews and Dissemination number: 42020193529).Method: Literature databases were searched through inception to August 2022. Randomised, controlled trials exploring adjunctive probiotics in adult chronic rhinosinusitis patients were included. From 948 records screened, 4 randomised, controlled trials were included.Results: Probiotics-associated adverse effects comprised epistaxis and abdominal pain. No reduction in Sino-Nasal Outcome Test values before 4 weeks (p = 0.58) or beyond 8 weeks (p = 0.08) of treatment or reduction of severe symptom frequency (p = 0.75) was observed. Symptom relapse in probiotic-treated patients was significantly lower across all timepoints (p = 0.045). Lower sinusitis relapse risks during treatment (risk ratio = 0.49; p = 0.019) and 8 months post-treatment (risk ratio = 0.56, p = 0.013) were observed. Probiotics demonstrated potential in improving Sino-Nasal Outcome Test symptom subscales, including sleep, psychological and rhinology subscales.Conclusion: The optimal mode of probiotic administration, treatment duration and target patient subgroups requires further study to evaluate the utility of probiotics.
- 14 October 2022
- Published by Stichting Nase in Rhinology Online
- Vol. 5 (5) , 142-148
Endotyping of nasal polyps in a multiracial Asian population
Background: Chronic rhinosinusitis is a heterogenous disease with variation in the endotypes of nasal polyps, with type 2 inflammation being more prevalent in Caucasian populations whereas Chinese populations are more heterogenous. We aim to describe the variation in endotypes for patients with chronic rhinosinusitis with nasal polyposis in our unique multiracial population. Methodology: Demographic, clinical and structured histopathological data of 66 patients who underwent sinus surgery for nasal polyposis were evaluated retrospectively. Results: 54.6% had eosinophilic disease, and 45.4% had non-eosinophilic disease with no significant demographic differences between the 2 populations. There were significantly higher peripheral eosinophil levels in patients with eosinophil-predominant inflammation on tissue histology (mean absolute eosinophil count 0.59 ± 0.18 x 109) compared with non-eosinophilic disease (mean absolute eosinophil count 0.24 ± 0.11 x 109). Structured histopathological reporting revealed that patients with eosinophilic disease had higher degree of inflammation and eosinophil aggregates. Conclusions: Our population is shown to have a slight preponderance toward eosinophilic disease, however the Chinese majority tended to have non-eosinophilic disease. Serum eosinophilia and the presence of asthma seems to correlate well with tissue eosinophilia, which can potentially be utilised as markers of type 2 inflammatory disease.
- 14 October 2022
- Published by Stichting Nase in Rhinology Online
- Vol. 5 (5) , 142-148
Endotyping of nasal polyps in a multiracial Asian population
Background: Chronic rhinosinusitis is a heterogenous disease with variation in the endotypes of nasal polyps, with type 2 inflammation being more prevalent in Caucasian populations whereas Chinese populations are more heterogenous. We aim to describe the variation in endotypes for patients with chronic rhinosinusitis with nasal polyposis in our unique multiracial population. Methodology: Demographic, clinical and structured histopathological data of 66 patients who underwent sinus surgery for nasal polyposis were evaluated retrospectively. Results: 54.6% had eosinophilic disease, and 45.4% had non-eosinophilic disease with no significant demographic differences between the 2 populations. There were significantly higher peripheral eosinophil levels in patients with eosinophil-predominant inflammation on tissue histology (mean absolute eosinophil count 0.59 ± 0.18 x 109) compared with non-eosinophilic disease (mean absolute eosinophil count 0.24 ± 0.11 x 109). Structured histopathological reporting revealed that patients with eosinophilic disease had higher degree of inflammation and eosinophil aggregates. Conclusions: Our population is shown to have a slight preponderance toward eosinophilic disease, however the Chinese majority tended to have non-eosinophilic disease. Serum eosinophilia and the presence of asthma seems to correlate well with tissue eosinophilia, which can potentially be utilised as markers of type 2 inflammatory disease.
- Top Cited PapersOpen Access
Prognosis and persistence of smell and taste dysfunction in patients with covid-19: meta-analysis with parametric cure modelling of recovery curves
Objective: To clarify in patients with covid-19 the recovery rate of smell and taste, proportion with persistent dysfunction of smell and taste, and prognostic factors associated with recovery of smell and taste. Design: Systematic review and meta-analysis. Data sources: PubMed, Embase, Scopus, Cochrane Library, and medRxiv from inception to 3 October 2021. Review methods: Two blinded reviewers selected observational studies of adults (≥18 years) with covid-19 related dysfunction of smell or taste. Descriptive prognosis studies with time-to-event curves and prognostic association studies of any prognostic factor were included. Data extraction and synthesis: Two reviewers extracted data, evaluated study bias using QUIPS, and appraised evidence quality using GRADE, following PRISMA and MOOSE reporting guidelines. Using iterative numerical algorithms, time-to-event individual patient data (IPD) were reconstructed and pooled to retrieve distribution-free summary survival curves, with recovery rates reported at 30 day intervals for participants who remained alive. To estimate the proportion with persistent smell and taste dysfunction, cure fractions from Weibull non-mixture cure models of plateaued survival curves were logit transformed and pooled in a two stage meta-analysis. Conventional aggregate data meta-analysis was performed to explore unadjusted associations of prognostic factors with recovery. Main outcome measures: The primary outcomes were the proportions of patients remaining with smell or taste dysfunction. Secondary outcomes were the odds ratios of prognostic variables associated with recovery of smell and taste. Results: 18 studies (3699 patients) from 4180 records were included in reconstructed IPD meta-analyses. Risk of bias was low to moderate; conclusions remained unaltered after exclusion of four high risk studies. Evidence quality was moderate to high. Based on parametric cure modelling, persistent self-reported smell and taste dysfunction could develop in an estimated 5.6% (95% confidence interval 2.7% to 11.0%, I 2 =70%, τ 2 =0.756, 95% prediction interval 0.7% to 33.5%) and 4.4% (1.2% to 14.6%, I 2 =67%, τ 2 =0.684, 95% prediction interval 0.0% to 49.0%) of patients, respectively. Sensitivity analyses suggest these could be underestimates. At 30, 60, 90, and 180 days, respectively, 74.1% (95% confidence interval 64.0% to 81.3%), 85.8% (77.6% to 90.9%), 90.0% (83.3% to 94.0%), and 95.7% (89.5% to 98.3%) of patients recovered their sense of smell (I 2 =0.0-77.2%, τ 2 =0.006-0.050) and 78.8% (70.5% to 84.7%), 87.7% (82.0% to 91.6%), 90.3% (83.5% to 94.3%), and 98.0% (92.2% to 95.5%) recovered their sense of taste (range of I 2 =0.0-72.1%, τ 2 =0.000-0.015). Women were less likely to recover their sense of smell (odds ratio 0.52, 95% confidence interval 0.37 to 0.72, seven studies, I 2 =20%, τ 2 =0.0224) and taste (0.31, 0.13 to 0.72, seven studies, I 2 =78%, τ 2 =0.5121) than men, and patients with greater initial severity of dysfunction (0.48, 0.31 to 0.73, five studies, I 2 =10%, τ 2 2 =0%, τ 2 <0.001) were less likely to recover their sense of smell. Conclusions: A substantial proportion of patients with covid-19 might develop long lasting change in their sense of smell or taste. This could contribute to the growing burden of long covid. Systematic review registration: PROSPERO CRD42021283922.
Top Cited PapersOpen AccessPrognosis and persistence of smell and taste dysfunction in patients with covid-19: meta-analysis with parametric cure modelling of recovery curves
Objective: To clarify in patients with covid-19 the recovery rate of smell and taste, proportion with persistent dysfunction of smell and taste, and prognostic factors associated with recovery of smell and taste. Design: Systematic review and meta-analysis. Data sources: PubMed, Embase, Scopus, Cochrane Library, and medRxiv from inception to 3 October 2021. Review methods: Two blinded reviewers selected observational studies of adults (≥18 years) with covid-19 related dysfunction of smell or taste. Descriptive prognosis studies with time-to-event curves and prognostic association studies of any prognostic factor were included. Data extraction and synthesis: Two reviewers extracted data, evaluated study bias using QUIPS, and appraised evidence quality using GRADE, following PRISMA and MOOSE reporting guidelines. Using iterative numerical algorithms, time-to-event individual patient data (IPD) were reconstructed and pooled to retrieve distribution-free summary survival curves, with recovery rates reported at 30 day intervals for participants who remained alive. To estimate the proportion with persistent smell and taste dysfunction, cure fractions from Weibull non-mixture cure models of plateaued survival curves were logit transformed and pooled in a two stage meta-analysis. Conventional aggregate data meta-analysis was performed to explore unadjusted associations of prognostic factors with recovery. Main outcome measures: The primary outcomes were the proportions of patients remaining with smell or taste dysfunction. Secondary outcomes were the odds ratios of prognostic variables associated with recovery of smell and taste. Results: 18 studies (3699 patients) from 4180 records were included in reconstructed IPD meta-analyses. Risk of bias was low to moderate; conclusions remained unaltered after exclusion of four high risk studies. Evidence quality was moderate to high. Based on parametric cure modelling, persistent self-reported smell and taste dysfunction could develop in an estimated 5.6% (95% confidence interval 2.7% to 11.0%, I 2 =70%, τ 2 =0.756, 95% prediction interval 0.7% to 33.5%) and 4.4% (1.2% to 14.6%, I 2 =67%, τ 2 =0.684, 95% prediction interval 0.0% to 49.0%) of patients, respectively. Sensitivity analyses suggest these could be underestimates. At 30, 60, 90, and 180 days, respectively, 74.1% (95% confidence interval 64.0% to 81.3%), 85.8% (77.6% to 90.9%), 90.0% (83.3% to 94.0%), and 95.7% (89.5% to 98.3%) of patients recovered their sense of smell (I 2 =0.0-77.2%, τ 2 =0.006-0.050) and 78.8% (70.5% to 84.7%), 87.7% (82.0% to 91.6%), 90.3% (83.5% to 94.3%), and 98.0% (92.2% to 95.5%) recovered their sense of taste (range of I 2 =0.0-72.1%, τ 2 =0.000-0.015). Women were less likely to recover their sense of smell (odds ratio 0.52, 95% confidence interval 0.37 to 0.72, seven studies, I 2 =20%, τ 2 =0.0224) and taste (0.31, 0.13 to 0.72, seven studies, I 2 =78%, τ 2 =0.5121) than men, and patients with greater initial severity of dysfunction (0.48, 0.31 to 0.73, five studies, I 2 =10%, τ 2 2 =0%, τ 2 <0.001) were less likely to recover their sense of smell. Conclusions: A substantial proportion of patients with covid-19 might develop long lasting change in their sense of smell or taste. This could contribute to the growing burden of long covid. Systematic review registration: PROSPERO CRD42021283922.
- Open Access
- 22 March 2022
- Published by Wiley in The Laryngoscope
- Vol. 132 (6) , 1260-1274
Neuroradiological Basis of COVID‐19 Olfactory Dysfunction: A Systematic Review and Meta‐Analysis
Objective: Olfactory dysfunction (OD) is a common presenting symptom of COVID‐19 infection. Radiological imaging of the olfactory structures in patients with COVID‐19 and OD can potentially shed light on its pathogenesis, and guide clinicians in prognostication and intervention.Methods: PubMed, Embase, Cochrane, SCOPUS were searched from inception to August 1, 2021. Three reviewers selected observational studies, case series, and case reports reporting radiological changes in the olfactory structures, detected on magnetic resonance imaging, computed tomography, or other imaging modalities, in patients aged ≥18 years with COVID‐19 infection and OD, following preferred reporting items for systematic reviews and meta‐analyses guidelines and a PROSPERO‐registered protocol (CRD42021275211). We described the proportion of radiological outcomes, and used random‐effects meta‐analyses to pool the prevalence of olfactory cleft opacification, olfactory bulb signal abnormalities, and olfactory mucosa abnormalities in patients with and without COVID‐19‐associated OD.Results: We included 7 case–control studies (N = 353), 11 case series (N = 154), and 12 case reports (N = 12). The pooled prevalence of olfactory cleft opacification in patients with COVID‐19 infection and OD (63%, 95% CI = 0.38–0.82) was significantly higher than that in controls (4%, 95% CI = 0.01–0.13). Conversely, similar proportions of cases and controls demonstrated olfactory bulb signal abnormalities (88% and 94%) and olfactory mucosa abnormalities (2% and 0%). Descriptive analysis found that 55.6% and 43.5% of patients with COVID‐19 infection and OD had morphological abnormalities of the olfactory bulb and olfactory nerve, respectively, while 60.0% had abnormal olfactory bulb volumes.Conclusion: Our findings implicate a conductive mechanism of OD, localized to the olfactory cleft, in approximately half of the affected COVID‐19 patients. Laryngoscope, 132:1260–1274, 2022
- 22 March 2022
- Published by Wiley in The Laryngoscope
- Vol. 132 (6) , 1260-1274
Open AccessNeuroradiological Basis of COVID‐19 Olfactory Dysfunction: A Systematic Review and Meta‐Analysis
Objective: Olfactory dysfunction (OD) is a common presenting symptom of COVID‐19 infection. Radiological imaging of the olfactory structures in patients with COVID‐19 and OD can potentially shed light on its pathogenesis, and guide clinicians in prognostication and intervention.Methods: PubMed, Embase, Cochrane, SCOPUS were searched from inception to August 1, 2021. Three reviewers selected observational studies, case series, and case reports reporting radiological changes in the olfactory structures, detected on magnetic resonance imaging, computed tomography, or other imaging modalities, in patients aged ≥18 years with COVID‐19 infection and OD, following preferred reporting items for systematic reviews and meta‐analyses guidelines and a PROSPERO‐registered protocol (CRD42021275211). We described the proportion of radiological outcomes, and used random‐effects meta‐analyses to pool the prevalence of olfactory cleft opacification, olfactory bulb signal abnormalities, and olfactory mucosa abnormalities in patients with and without COVID‐19‐associated OD.Results: We included 7 case–control studies (N = 353), 11 case series (N = 154), and 12 case reports (N = 12). The pooled prevalence of olfactory cleft opacification in patients with COVID‐19 infection and OD (63%, 95% CI = 0.38–0.82) was significantly higher than that in controls (4%, 95% CI = 0.01–0.13). Conversely, similar proportions of cases and controls demonstrated olfactory bulb signal abnormalities (88% and 94%) and olfactory mucosa abnormalities (2% and 0%). Descriptive analysis found that 55.6% and 43.5% of patients with COVID‐19 infection and OD had morphological abnormalities of the olfactory bulb and olfactory nerve, respectively, while 60.0% had abnormal olfactory bulb volumes.Conclusion: Our findings implicate a conductive mechanism of OD, localized to the olfactory cleft, in approximately half of the affected COVID‐19 patients. Laryngoscope, 132:1260–1274, 2022